Freedom of Information Request: 0197 2019/20

Under the terms of Freedom of Information Act, I would like to request information regarding the performance of the chemotherapy drug: Trabectedin (Yondelis). In particular, I am keen to understand the performance rates for patients with low grade well-differentiated retroperitoneal lipsarcoma. This should include patient numbers, tumour shrinkage rates and average life expectancy on the drug.

79 patients who had been diagnosed with low grade well-differentiated retroperitoneal liposarcoma (ICD10 code C480) were treated with Trabectedin (Yondelis), the earliest being 2014, the latest in June. Of these, the average days to death since the above drug was first administered was 301. We do not record tumour shrinkage rates.